Caprion Pharmaceuticals Announces Disease Biomarker Research Collaboration with AstraZeneca
August 11, 2003, Montreal, Canada - Caprion Pharmaceuticals today announced a research collaboration with AstraZeneca (NYSE: AZN) to identify biomarkers for pain using Caprion's CellCartaTM proteomics discovery platform.
Under the terms of the agreement, Caprion will profile the proteomic changes occurring in plasma resulting from the administration of pharmaceutical compounds in relevant preclinical models. There are few reliable molecular markers of pain, and the companies believe that the discovery of one or several pain biomarkers could have a significant impact on the treatment of pain.
"We are very pleased to begin this relationship with Caprion," said Dr. Philippe Walker, Vice President, Discovery at AstraZeneca R&D Montréal. "We believe that Caprion's proteomics platform is well suited to identify novel biomarkers that could be used to assess the safety and efficacy of AstraZeneca's experimental compounds."
"This collaboration represents yet another important disease biomarker discovery program for Caprion," noted Dr. Daniel Chelsky, Chief Scientific Officer of Caprion Pharmaceuticals. "This study, and AstraZeneca's support and participation in it, illustrates how Caprion's biomarker discovery capability addresses many key pharmaceutical needs, including predicting efficacy and safety, stratifying patient populations, elucidating mechanism of action, optimizing dosage regime, and managing treatment progression."
Caprion's proprietary proteomics technology comprehensively and quantitatively profiles the proteins contained in tissues and blood. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies.
Caprion Pharmaceuticals is a leader in proteomics-based drug discovery. The Company's proprietary technology platform comprehensively profiles human tissues and serum by integrating proprietary organelle isolation and sample decomplexification, quantitative mass spectrometry, and advanced bioinformatics. Its drug discovery programs are focused on Tumor Antigen Discovery, Biomarker Discovery, and Compound Mechanism of Action elucidation. Last month, Caprion announced a biomarker discovery agreement with Wyeth (NYSE: WYE). In addition, Caprion announced a collaboration in September 2002 with IDEC Pharmaceuticals (Nasdaq: IDPH) to use its protein profiling technology to identify tumor antigen targets for colon cancer. The Company has also partnered products for Mad Cow Disease and variant Creutzfeldt-Jacob Disease diagnostics, in development with IDEXX Laboratories and Ortho-Clinical Diagnostics. For more on Caprion, see www.caprion.com.
AstraZeneca is a major international pharmaceutical company engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with sales of over US$17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. Skilled research is at the heart of AstraZeneca's continuing success with over 11,000 R&D employees worldwide and an annual investment of more than $3.1 billion dedicated to the discovery and development of new and improved medicines. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit www.astrazeneca.com
FOR MORE INFORMATION, CONTACT:
Caprion Pharmaceuticals Inc.
Chief Financial Officer